Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I PK comparability study of MYL-1402O versus EU and US Avastin in healthy male volunteers
NL-OMON42579Phase 1Active, not recruiting
- Sponsor
- Mylan
- Start
- Mar 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MYL-1402O and bevacizumab in cancer (3 arms), sponsored by Mylan. Primary endpoint: Pharmacokinetic comparability. Started Mar 2015; status: active, not recruiting.
02
Drugs
MYL-1402Obevacizumab
03
Conditions
cancer
Beyond the preview
Go deeper on NL-OMON42579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42579.